| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/24/2005 | WO2005025647A2 Medication delivery device |
| 03/24/2005 | WO2005025622A1 Bitterness-masking particulate jelly beverage |
| 03/24/2005 | WO2005025621A1 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| 03/24/2005 | WO2005025609A1 Lactoferrin material composition |
| 03/24/2005 | WO2005025578A1 Use of ciclesonide for the treatment of respiratory diseases |
| 03/24/2005 | WO2005025575A1 Protective solution used during eye treatments |
| 03/24/2005 | WO2005025566A1 Oral pharmaceutical formulations containing the active ingredient irbesartan |
| 03/24/2005 | WO2005025564A1 Oral pharmaceutical formulations of rofecoxib |
| 03/24/2005 | WO2005025560A1 Ophthalmic composition |
| 03/24/2005 | WO2005025559A1 Treatment of gastroparesis and nonulcer dyspepsia with gabab agonists |
| 03/24/2005 | WO2005025553A2 Treatment of disorders of nervous systemsystem with fty720 |
| 03/24/2005 | WO2005025551A2 Pharmaceutical products comprising bisphosphonates |
| 03/24/2005 | WO2005025549A2 Multi-layer transdermal drug delivery device |
| 03/24/2005 | WO2005025548A1 Topical preparations comprising a hydrophilic carrier and a silicone matrix |
| 03/24/2005 | WO2005025547A1 Medicinal skin adhesives containing essential oils for the treatment of common colds, and method for the production thereof |
| 03/24/2005 | WO2005025546A1 Agent containing ergolin for transdermal application |
| 03/24/2005 | WO2005025545A2 Pharmaceutical formulation for controlled release of selodenoson |
| 03/24/2005 | WO2005025544A1 Enteric delivery of (-)-hydroxycitric acid |
| 03/24/2005 | WO2005025543A2 Polymer-based sustained release device and method for preparation |
| 03/24/2005 | WO2005025542A1 Fine grain having fat-soluble drug encapsulated therein, process for producing the same and preparation containing the same |
| 03/24/2005 | WO2005025541A2 Dry powder composition comprising a benzodiazepine for pulmonary inhalation |
| 03/24/2005 | WO2005025536A2 Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
| 03/24/2005 | WO2005025535A2 Methods for preparing pharmaceutical compositions |
| 03/24/2005 | WO2005025503A2 A composition and method of treatment for urogenital conditions |
| 03/24/2005 | WO2005025501A2 Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 03/24/2005 | WO2005025500A2 Process for preparing water soluble diterpenes and their applications |
| 03/24/2005 | WO2005025498A2 Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation |
| 03/24/2005 | WO2005025488A2 Methods for the controlled delivery of pharmacologically active compounds |
| 03/24/2005 | WO2005025336A1 Pellets comprising a swellable substrate, used as an oral dosage form for dietary fibre |
| 03/24/2005 | WO2005011640A3 Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
| 03/24/2005 | WO2005011614A3 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| 03/24/2005 | WO2005009411A3 Particles containing an active agent in the form of a co-precipitate |
| 03/24/2005 | WO2005002553A3 Fluconazole capsules with improved release |
| 03/24/2005 | WO2005000324A3 Colloidal silver composition having antimicrobial properties |
| 03/24/2005 | WO2005000237A3 Granules containing biologically active substances |
| 03/24/2005 | WO2004112759A3 Skin patches |
| 03/24/2005 | WO2004112713A3 Drug polymer complexes |
| 03/24/2005 | WO2004111194A3 Method to increase protein production in culture |
| 03/24/2005 | WO2004110497A3 Mitomycin conjugates cleavable by thiols |
| 03/24/2005 | WO2004108792A3 Novel biodegradable aliphatic polyesters and pharmaceutical compositions and applications thereof |
| 03/24/2005 | WO2004108265A3 Nanoparticles from supercritical fluid antisolvent process using particle growth and agglomeration retardants |
| 03/24/2005 | WO2004108089A3 A micro granulate formulation for oral administration in aqueous suspension |
| 03/24/2005 | WO2004108082A3 Controlled release formulations |
| 03/24/2005 | WO2004103291A3 Extended release compositions of proton pump inhibitor |
| 03/24/2005 | WO2004103277A3 Novel composition for hormonal balance and uses thereof |
| 03/24/2005 | WO2004103266A3 Protein kinase c peptides for use in withdrawal |
| 03/24/2005 | WO2004100927A8 Injectable depots consisting of liposomal aggregates for the delivery of active substances |
| 03/24/2005 | WO2004096176A3 Solid drug formulation and device for storage and controlled delivery thereof |
| 03/24/2005 | WO2004091546A3 Central nervous system stimulant and opioid antagonist combinations |
| 03/24/2005 | WO2004091528B1 Delivery systems of homogeneous thermoreversible alginate films |
| 03/24/2005 | WO2004087648A3 Stabilized phenytoin containing composition |
| 03/24/2005 | WO2004084860A3 Methods for the comminution and stabilization of small particles in suspension |
| 03/24/2005 | WO2004084839A3 Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
| 03/24/2005 | WO2004080382A3 Novel compositions containing fentanyl |
| 03/24/2005 | WO2004075834A3 Stabilized pharmaceutical compositions of safingol and methods of using the same |
| 03/24/2005 | WO2004073643A3 Estradiol metabolites for the treatment of pulmonary hypertension |
| 03/24/2005 | WO2004071415A3 Method for treating elevated intraocular pressure, including glaucoma |
| 03/24/2005 | WO2004071410A3 Lyophilization method and apparatus for producing particles |
| 03/24/2005 | WO2004069888A3 Block copolymers |
| 03/24/2005 | WO2004068511A3 Formation of superparamagnetic particles |
| 03/24/2005 | WO2004066978A8 Powder pharmaceutical compositions |
| 03/24/2005 | WO2004064788A3 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| 03/24/2005 | WO2004052289A3 Multilayered tablet containing pravastatin and aspirin |
| 03/24/2005 | WO2004050072A8 Water-soluble composition containing coenzyme q10 |
| 03/24/2005 | WO2004024777A8 Hydroxyalkyl starch derivatives |
| 03/24/2005 | WO2004000197A3 Quick dissolve compositions and tablets based thereon |
| 03/24/2005 | WO2003077972A8 Implantable drug delivery system |
| 03/24/2005 | WO2003077861A3 Water-based delivery systems |
| 03/24/2005 | US20050065817 Separation of validated information and functions in a healthcare system |
| 03/24/2005 | US20050065500 Electroactive polymer actuated medication infusion pumps |
| 03/24/2005 | US20050065486 Adhesive structures for attachment to skin |
| 03/24/2005 | US20050065465 Safety limits for closed-loop infusion pump control |
| 03/24/2005 | US20050065308 Mold inhibitor integrated within a matrix and method of making same |
| 03/24/2005 | US20050065183 Bioavailability; mixture containing lactose and hydroxypropyl cellulose |
| 03/24/2005 | US20050065175 Oral transmucosal methadone |
| 03/24/2005 | US20050065172 Micxture of caffeine and a cephalin; controlling particle size; high speed dissolving |
| 03/24/2005 | US20050065148 Dipeptidyl peptidase inhibitors |
| 03/24/2005 | US20050065137 Triamcinolone acetonide and anecortave acetate formulations for injection |
| 03/24/2005 | US20050065116 Thiazolopyrimidines useful as TNFalpha inhibitors |
| 03/24/2005 | US20050065112 Antiproliferative agents; low toxicity; psoriasis; antitumor agents; rheumatic arthritis; gastrointestinal disorders; antiinflamamtory agents |
| 03/24/2005 | US20050065091 Containing antioxidant, free radical scavenger ; topical solution containing vitamin c, vitamin e |
| 03/24/2005 | US20050065069 Use of hcg in controlled ovarian hyperstimulation |
| 03/24/2005 | US20050065062 Method of formulating a pharmaceutical composition |
| 03/24/2005 | US20050064595 Silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell; stable nucleic acid-lipid particles (SNALP) |
| 03/24/2005 | US20050064460 Emulsion compositions |
| 03/24/2005 | US20050064045 Chemical ablation agent to cause tissue necrosis, and a biodegradable viscosity agent to form a highly viscous formulation for injection; prostatic ablation to treat benign prostatic hyperplasia |
| 03/24/2005 | US20050064039 Novel microsphere and method for production thereof |
| 03/24/2005 | US20050064038 Two or more active agents (drugs) in a layer of a miscible polymer blend where delivery of one active agent occurs faster due to its greater permeability than the other drugs; medical devices such as stents; versatility in mechanical properties, active agents |
| 03/24/2005 | US20050064037 Transdermal delivery of oxybutynin in gel formulations |
| 03/24/2005 | US20050064036 Methods of treatment using a gastric retained gabapentin dosage |
| 03/24/2005 | US20050064035 Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| 03/24/2005 | US20050064034 Oral extended-release composition |
| 03/24/2005 | US20050064033 Such as clarithromycin, orally in combination with a polymer, with release in the gastrointestinal environment with lower mean fluctuation index in the plasma than with an immediate release formulation, but equivalent bioavailability; gastrointestinal side effect reduction, taste |
| 03/24/2005 | US20050064032 Dosage form, device, and methods of treatment |
| 03/24/2005 | US20050064030 Making a tablet by combining a drug with an effervescent agent used as penetration enhancer to influence the permeability of the medicament in the oral cavity; compressing to form tablet |
| 03/24/2005 | US20050064029 Stable pharmaceutical composition |
| 03/24/2005 | US20050064028 Pharmaceutical compositions containing plasma protein |
| 03/24/2005 | US20050064027 Prolonged gastric retention time due to bioadhesion (which may be polymers, metal oxides, or ligands for specific mucosal components); macrospheres for delivery of acyclovir for example |
| 03/24/2005 | US20050064026 Mixture of low polydispersity, contain a cationic lipid such as DC-chloesterol and a neutral amphiphile such as DOPE (dioleoylphosphatidyl ethanolamine); use in gene therapy for delivery of nucleic acids; making by continuous low pressure extrusion |
| 03/24/2005 | US20050064024 High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them |